Is UiPath (PATH) Offering Value After Recent Share Price Declines And DCF Upside Estimate

  • If you are wondering whether UiPath's current share price matches its long term potential, looking closely at how the market is valuing its automation story is a good place to start.
  • The stock recently closed at US$14.20, with returns of a 7.6% decline over the last week, a 15.0% decline over the last month, a 10.6% decline year to date, a 5.6% gain over the past year, and roughly flat performance over three years at 0.1%.
  • Recent coverage has focused on UiPath's position in enterprise automation and how customers are using its platform to streamline workflows. This helps explain why sentiment can shift quickly and these headlines give useful context for the share price moves, even without new earnings guidance on the table.
  • UiPath currently scores 3 out of 6 on our valuation checks for being undervalued, giving it a value score of 3. Next we will look at how different valuation methods line up on the stock before finishing with a framework that can help you make even more sense of those numbers.

UiPath delivered 5.6% returns over the last year. See how this stacks up to the rest of the Software industry.

Advertisement

Approach 1: UiPath Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes the cash UiPath is expected to generate in the future, then discounts those projections back to today to estimate what the business could be worth right now.

UiPath’s latest twelve month free cash flow is about $319.9 million. Analysts and model estimates project free cash flow rising to $368.7 million in 2026 and $419.9 million in 2027, reaching $471.2 million by 2028. Beyond that, Simply Wall St extrapolates cash flows out to 2035 using a 2 Stage Free Cash Flow to Equity model, with each year’s cash flow discounted back to today.

Putting those projections together, the DCF model arrives at an estimated intrinsic value of about $17.78 per share. Compared with the recent share price of $14.20, that implies a 20.1% discount, which indicates UiPath shares are currently trading below this cash flow based estimate of fair value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests UiPath is undervalued by 20.1%. Track this in your watchlist or portfolio, or discover 881 more undervalued stocks based on cash flows.

PATH Discounted Cash Flow as at Jan 2026
PATH Discounted Cash Flow as at Jan 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for UiPath.

Approach 2: UiPath Price vs Earnings

For profitable companies, the P/E ratio is a practical way to think about valuation because it links what you pay for each share directly to the earnings that business is generating today.

What counts as a “normal” P/E depends a lot on how the market sees the company’s growth potential and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while slower expected growth or higher risk often lines up with a lower multiple.

UiPath currently trades on a P/E of 33.1x. That sits above the broader Software industry average of 30.9x, and below the peer group average of 53.7x. Those comparisons are useful, but they are quite broad and do not fully reflect UiPath’s specific earnings profile.

Simply Wall St’s Fair Ratio of 14.4x is a proprietary estimate of what UiPath’s P/E might be given its earnings growth characteristics, industry, profit margins, market cap and risk factors. Because it is tailored to the company’s own fundamentals, this Fair Ratio is more targeted than a simple industry or peer comparison.

With the current P/E of 33.1x sitting well above the Fair Ratio of 14.4x, this multiple-based view suggests the shares are trading richer than this model would expect.

Result: OVERVALUED

NYSE:PATH P/E Ratio as at Jan 2026
NYSE:PATH P/E Ratio as at Jan 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1447 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your UiPath Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives.

A Narrative is simply your story about a company, written in numbers as well as words, where you link your view on its products, competition and risks to explicit assumptions about future revenue, earnings and margins.

On Simply Wall St, Narratives live on the Community page and help you turn that story into a financial forecast and a fair value estimate that you can compare directly with the current share price to decide whether the stock looks attractive, fully priced or expensive for you.

Because Narratives update when new information such as news or earnings is added, you can keep your view current without rebuilding your thinking from scratch. You can also see how other investors may rate UiPath very differently based on their own assumptions. For example, one Narrative might see a fair value well above US$17.78, while another might see it well below the recent US$14.20 price.

Do you think there's more to the story for UiPath? Head over to our Community to see what others are saying!

NYSE:PATH 1-Year Stock Price Chart
NYSE:PATH 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:PATH

UiPath

Provides an automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
50 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7719.9% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
24 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.9% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
85 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
193 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0